Graypoint LLC Has $422,000 Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Graypoint LLC decreased its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 17.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,996 shares of the medical equipment provider’s stock after selling 833 shares during the quarter. Graypoint LLC’s holdings in Zimmer Biomet were worth $422,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Dunhill Financial LLC boosted its stake in shares of Zimmer Biomet by 1,090.0% during the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 218 shares during the last quarter. Ashton Thomas Securities LLC acquired a new position in Zimmer Biomet during the third quarter valued at approximately $28,000. Bangor Savings Bank bought a new position in Zimmer Biomet in the third quarter valued at approximately $31,000. Brooklyn Investment Group acquired a new position in shares of Zimmer Biomet during the 3rd quarter worth approximately $35,000. Finally, Quarry LP bought a new stake in shares of Zimmer Biomet during the 2nd quarter worth approximately $53,000. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Up 2.9 %

Shares of ZBH opened at $104.47 on Friday. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38. The stock has a market capitalization of $20.80 billion, a PE ratio of 19.86, a P/E/G ratio of 1.96 and a beta of 1.02. The firm’s 50 day moving average is $108.03 and its 200-day moving average is $108.02. Zimmer Biomet Holdings, Inc. has a 12 month low of $100.67 and a 12 month high of $133.90.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.74. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The firm had revenue of $1.82 billion during the quarter, compared to the consensus estimate of $1.80 billion. During the same period in the prior year, the company posted $1.65 EPS. The company’s revenue was up 4.1% compared to the same quarter last year. Equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Monday, December 30th will be given a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 0.92%. The ex-dividend date of this dividend is Monday, December 30th. Zimmer Biomet’s payout ratio is presently 18.25%.

Analyst Ratings Changes

ZBH has been the subject of several analyst reports. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research note on Thursday, October 31st. BTIG Research lowered their price objective on shares of Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating on the stock in a research note on Thursday, October 3rd. Evercore ISI cut their target price on shares of Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating for the company in a research note on Tuesday, October 1st. Truist Financial boosted their price target on Zimmer Biomet from $117.00 to $118.00 and gave the stock a “hold” rating in a research report on Wednesday, December 18th. Finally, Barclays reduced their target price on Zimmer Biomet from $125.00 to $118.00 and set an “underweight” rating for the company in a research note on Thursday, December 12th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $123.33.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.